Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial
Evan Alley(Penn Presbyterian Medical Center), Juanita Lopez(Institute of Cancer Research), Armando Santoro(Humanitas University), Anne Morosky(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sanatan Saraf(Merck & Co., Inc., Rahway, NJ, USA (United States)), Bilal Piperdi(Merck & Co., Inc., Rahway, NJ, USA (United States)), Emilie M.J. van Brummelen(Dutch Cancer Society)
Cited by 491
Abstract
Related Papers
No related papers found
Powered by citation graph analysis